Viktor Grünwald
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Renal cell carcinoma treatment
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Prostate Cancer Treatment and Research
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Renal cell carcinoma treatment 172
- Sarcoma Diagnosis and Treatment 24
- Prostate Cancer Treatment and Research 13
- Prostate Cancer Diagnosis and Treatment 8
- Oncology 60
- Cancer Immunotherapy and Biomarkers 31
- Cancer survivorship and care 10
- Co-authors
- Camillo Porta (29 shared papers)Bernard J. Escudier (24 shared papers)Manuel M. Hidalgo (7 shared papers)Robert John Motzer (21 shared papers)Sergio Bracarda (11 shared papers)Thomas E. Hutson (15 shared papers)Alain Ravaud (9 shared papers)Stéphane Marie. Oudard (6 shared papers)
- Journals
- Annals of Oncology (39 papers)European Journal of Cancer (23 papers)European Urology (15 papers)World Journal of Urology (14 papers)The Lancet Oncology (10 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Viktor Grünwald
299 papers receiving 15.5k citations
Viktor Grünwald's Hit Papers
Peers
Comparison fields: 5 of 127
- Pulmonary and Respiratory Medicine 8.7k
- Oncology 3.2k
- Otorhinolaryngology 351
- Cancer Research 542
- Gastroenterology 264
Countries citing papers authored by Viktor Grünwald
This map shows the geographic impact of Viktor Grünwald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Viktor Grünwald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Viktor Grünwald more than expected).
Fields of papers citing papers by Viktor Grünwald
This network shows the impact of papers produced by Viktor Grünwald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Viktor Grünwald. The network helps show where Viktor Grünwald may publish in the future.
Co-authors
The 25 scholars most cited alongside Viktor Grünwald, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 326 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2537 |
| 2 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Hit paper breakdown → | 2021 | 1353 |
| 3 | Phase 3 trial of everolimus for metastatic renal cell carcinoma Hit paper breakdown → | 2010 | 981 |
| 4 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2019 | 879 |
| 5 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Hit paper breakdown → | 2019 | 657 |
| 6 | Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial Hit paper breakdown → | 2017 | 349 |
| 7 | 2016 | 343 | |
| 8 | 2003 | 319 | |
| 9 | Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. | 2002 | 239 |
| 10 | 2014 | 227 | |
| 11 | 2018 | 225 | |
| 12 | 2019 | 213 | |
| 13 | Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma Hit paper breakdown → | 2022 | 212 |
| 14 | 2011 | 200 | |
| 15 | 2013 | 195 | |
| 16 | Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2024 | 192 |
| 17 | 2020 | 191 | |
| 18 | 2016 | 182 | |
| 19 | 2016 | 161 | |
| 20 | 2021 | 160 |
About Viktor Grünwald
Viktor Grünwald is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Otorhinolaryngology, Surgery and Radiology, Nuclear Medicine and Imaging, having authored 326 papers that have together received 15.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (172 papers), Cancer Immunotherapy and Biomarkers (31 papers), Sarcoma Diagnosis and Treatment (24 papers), Bladder and Urothelial Cancer Treatments (20 papers), Head and Neck Cancer Studies (14 papers), Prostate Cancer Treatment and Research (13 papers), Cancer survivorship and care (10 papers) and Prostate Cancer Diagnosis and Treatment (8 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (8.7k citations), Oncology (3.2k citations), Otorhinolaryngology (351 citations), Cancer Research (542 citations) and Gastroenterology (264 citations). Viktor Grünwald has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Camillo Porta, Bernard J. Escudier, Manuel M. Hidalgo, Robert John Motzer, Sergio Bracarda, Thomas E. Hutson, Alain Ravaud, Stéphane Marie. Oudard, Robert A. Figlin and John A. Thompson. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, European Urology, World Journal of Urology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.